Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Status: complete

The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.

Inclusion Criteria

Men & women ≥20 years of age
Histologically confirmed unresectable advanced or recurrent esophageal cancer
Refractory to or intolerant of standard therapy
ECOG Performance Status score 0 or 1
A life expectancy of at least 3 months

Exclusion Criteria

Current or past history of severe hypersensitivity to any other antibody products
Patients with multiple primary cancers
Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment
Patients with active, known or suspected autoimmune disease

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.